Yang Jiayan, Yu Jiangquan, Zheng Ruiqiang
Yangzhou Clinical College of Dalian Medical University, Yangzhou 225001, Jiangsu, China.
Department of Intensive Care Unit, Northern Jiangsu People's Hospital, Yangzhou 225001, Jiangsu, China. Corresponding author: Yu Jiangquan, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024 Jul;36(7):774-777. doi: 10.3760/cma.j.cn121430-20231009-00852.
Sepsis is a life-threatening organ dysfunction caused by the host's dysfunctional response to infection. Sepsis-induced cardiomyopathy (SICM), as a serious complication of sepsis, is an acute reversible cardiac dysfunction syndrome unrelated to myocardial ischemia, which affects the outcome and prognosis of sepsis. As a complex microbial system, gut microbiota has been confirmed to be involved in the development of coronary heart disease, hypertension, heart failure and other cardiovascular diseases, and is also related to the occurrence and development of sepsis. However, there are few studies on the relationship between gut microbiota and SICM. This paper reviews the current research progress on gut microbiota and SICM, aiming at provide a new idea for clinical treatment of SICM.
脓毒症是由宿主对感染的功能失调反应引起的危及生命的器官功能障碍。脓毒症诱导的心肌病(SICM)作为脓毒症的一种严重并发症,是一种与心肌缺血无关的急性可逆性心脏功能障碍综合征,它会影响脓毒症的结局和预后。作为一个复杂的微生物系统,肠道微生物群已被证实与冠心病、高血压、心力衰竭等心血管疾病的发生发展有关,也与脓毒症的发生发展有关。然而,关于肠道微生物群与SICM之间关系的研究较少。本文综述了肠道微生物群与SICM的当前研究进展,旨在为SICM的临床治疗提供新思路。